Serum Endocan Levels and Gestational Diabetes

Sponsor

Gaziosmanpasa Research and Education Hospital (Other)

Overall Status

Completed

CT.gov ID

NCT05237895

Collaborator

(none)

Enrollment

Location

Arms

2.1

Actual Duration (Months)

43.5

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

In diabetic patients, serum endocan level has been significantly increased in patients and the levels on the long-term complications are correlated. Based on the Iinformation obtained from these studies, it can be said that there is a strong association between diabetes and serum endocan levels.

Condition or Disease	Intervention/Treatment	Phase
Gestational Diabetes Endocan	Diagnostic Test: Serum Endocan Levels	N/A

Detailed Description

It has been shown that endocan level of plasental tissue in gestational diabtes patients is significantly increased when looking at the same week compared with plasenta tissue samples of helathy pregnancy. From the information obtained from these studies, it can be said that there is a strong association between diabetes mellitus and serum endocan levels. investigators aimed to determine the relationship between serum endocan levels and gestational diabetes in the study.

Study Design

Study Type:

Interventional

Actual Enrollment :

90 participants

Allocation:

Non-Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Diagnostic

Official Title:

Evaluation of Serum Endocan Levels in Patients With Gestational Diabetes

Actual Study Start Date :

Mar 3, 2022

Actual Primary Completion Date :

May 5, 2022

Actual Study Completion Date :

May 5, 2022

Arms and Interventions

Arm	Intervention/Treatment
Other: Patients with Gestational Diabetes pregnant women who are at 24-26 weeks of gestational age with positive oral glucose tolerance screening test.	Diagnostic Test: Serum Endocan Levels Detection of Serum Endocan Levels and detection of possible diagnostic association with gestational diabetes
Other: Healty Pregnants pregnant women who are at 24-26 weeks of gestational age with normal oral glucose tolerance screening test.	Diagnostic Test: Serum Endocan Levels Detection of Serum Endocan Levels and detection of possible diagnostic association with gestational diabetes

Arm

Intervention/Treatment

Other: Patients with Gestational Diabetes

pregnant women who are at 24-26 weeks of gestational age with positive oral glucose tolerance screening test.

Diagnostic Test: Serum Endocan Levels

Detection of Serum Endocan Levels and detection of possible diagnostic association with gestational diabetes

Other: Healty Pregnants

pregnant women who are at 24-26 weeks of gestational age with normal oral glucose tolerance screening test.

Diagnostic Test: Serum Endocan Levels

Detection of Serum Endocan Levels and detection of possible diagnostic association with gestational diabetes

Outcome Measures

Primary Outcome Measures

Detection of diagnostic value of serum endocan levels in patient with gestational diabetes [3 months]
Identifying diagnostic value of serum endocan by comparing serum levels of endocan in groups.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 45 Years

Sexes Eligible for Study:

Female

Accepts Healthy Volunteers:

Inclusion Criteria:

being pregnant at 24-26 weeks of gestation
having oral glucose toleranse screening test
age between 18-45 years

Exclusion Criteria:

having in utero mort fetus
having a previous diagnosis of diabetes
having a multiple pregnancy
having a coronary artery disease
having preeclampcia
having a pregnancy obtained by assisted reproductive technology
using cigarette
using alcohol

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Gaziosmanpaşa Treh	Istanbul	Gaziosmanpaşa	Turkey	34000

Sponsors and Collaborators

Gaziosmanpasa Research and Education Hospital

Investigators

Principal Investigator: elif yıldız, MD, Gaziosmanpasa Research and Education Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Elif Yıldız, Principal investigator, Gaziosmanpasa Research and Education Hospital

ClinicalTrials.gov Identifier:

NCT05237895

Other Study ID Numbers:

GaziosmanpaşaTREHi

First Posted:

Feb 14, 2022

Last Update Posted:

Aug 5, 2022

Last Verified:

Aug 1, 2022

Individual Participant Data (IPD) Sharing Statement:

Plan to Share IPD:

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Additional relevant MeSH terms:

Diabetes, Gestational

Diabetes Mellitus

Study Results

No Results Posted as of Aug 5, 2022